Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News


Cellerant Awarded SBIR Contract Funding to Develop CLT-009 for Treatment of Thrombocytopenia 

 

 

Cellerant Awarded SBIR Contract Funding to Develop CLT-009 for Treatment of Thrombocytopenia

October 8, 2012 - (Cellerant) - "Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase 1 contract and a Phase 2 option from the National Cancer Institute (NCI) valued up to $1,683,503."  Read Full Article

 

Posted on 18-Oct-12 by Gallerno, Jacob
Tags: Science and Industry News
 
Trackback Url  |  Link to this post | Bookmark this post with: